|
|
 |
|
Viewing report
|
|
|
|
Novartis: Performance - Products - Pipeline - Potential
Espicom Business Intelligence Ltd, Nov 2009, Pages: 268
Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.
Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field and has operations in approximately 140 countries worldwide. Novartis is currently organised into the four divisions of Pharmaceuticals, Consumer Health, Sandoz, and Vaccines & Diagnostics, created following the acquisition of Chiron Corporation. Within Pharmaceuticals, the company's current growth drivers include Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa (zoledronate).
Novartis delivered a steady performance in 2008. Operating income was down by 30.1 per cent and net income down by 31.2 per cent. Within Pharmaceuticals, Novartis' strategic products such as Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa (zoledronate) continued to perform well, while Consumer Health benefited from the North American OTC business of Bristol-Myers Squibb which was acquired in 2005. Sales at Sandoz increased by 20.3 per cent due to the continued effects of the Hexal and Eon Labs acquisitions, which have made it a world leader in generics.
In the longer term, as a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a total of 139 compounds under development. With a number of projects in late-stage development, of particular note is fingolimod, which is under Phase III development for multiple sclerosis.
This new strategic analysis report Novartis: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Customers who bought this item also bought
Incontinence Products in the United States
Dainippon Sumitomo: Performance, Products, Pipeline and Potential
Roche - Pipeline - Products - Performance - Potential
PharmaVitae 2004: Roche Global and US Analysis
Bayer: Performance, Products, Pipeline and Potential
Chinese Markets for Laundry Care Products
Shionogi: Performance, Products, Pipeline and Potential
sanofi-aventis - Pipeline - Products - Performance - Potential
|
|
|
|
